Is anyone involved in clinical trials for ET, specifically for CALR?
Is anyone involved in any clinical trials for ET, specifically for CALR? I am unable to tolerate Hydroxyurea, and am currently only taking aspirin. I saw this one: “JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms” on clinical trials.gov and other cancer center sites.
Interested in more discussions like this? Go to the Blood Cancers & Disorders Support Group.
Connect

@janemc yes! And even when platelet counts are within normal limits, our bone marrow is still doing its thing, at risk for scarring and myelofibrosis.
-
Like -
Helpful -
Hug
2 Reactions@loribmt, @patty1962 I am waiting for sponsor approval for either of these clinical trials at MD Anderson. I don’t know how long I am expected to wait-I was evaluated mid-March. I am holding off on starting methotrexate for arthritis and other aches and pains. I think since it is an immunosuppressant (and also used as a treatment for cancer at higher doses) methotrexate may disqualify me from participating in a clinical trial. I’ve been waiting about 2 weeks for a definitive answer from the research team regarding this. If not accepted, I will probably start on Jakafi, and the methotrexate.
-
Like -
Helpful -
Hug
3 ReactionsAlso, we are still at risk for blood clots even when platelet counts are within normal limits. Some more than others depending on which mutation is present.
-
Like -
Helpful -
Hug
2 Reactions@lisanell Which mutations are more likely to have blood clots? (I didn't know that some are more likely than others. I had one removed from my carotid artery 3 years ago and I am MPL mutation)
@kapow
Your vulnerability to blood clots depends on SO MANY factors.
Speaking very generally: Relative to those with the JAK2 driver, MPLs like you and me, as well as CALs and triple-negatives, are less prone to clots.
But, compared to everyone who doesn't have it, anyone with ET has an increased risk of clots.
Remember! Every time you take the meds prescribed by your doctor
-- you are saying NO THANK YOU to blood clots.
Some helpful background from Blood Cancer UK:
********************
When you have ET, your body starts making too many blood cells called platelets.
Platelets are blood cells that help your blood to clot. They stick together to stop you bleeding if you have a cut or a bruise.
Like most blood cells, platelets are made inside your bone marrow – the spongy material inside some of your bones. Large cells in your bone marrow called megakaryocytes produce platelets that are released into your bloodstream, ready to stop the bleeding if you are injured.
In ET, the megakaryocytes start to make too many platelets. That means your blood may clot too easily. This can cause a heart attack or stroke and a range of other symptoms.
Treatments for ET aim to manage these symptoms and lower your risk of developing blood clots.
**********************
-
Like -
Helpful -
Hug
4 Reactions@janemc Thank you for this explanation. I guess I am proof that it doesn’t really matter which driver mutation you have, blood clots are possible and our enemy. Keeping the platelet count down by following our doctor’s instructions on medication is very important. And has been stated several times …..everyone is different.
-
Like -
Helpful -
Hug
4 Reactions@kapow JAK2 and MPL mutations have been associated with a higher risk of both venous and arterial blood clots, then triple negative, and then CALr being associated with a lower risk of both type clots. My point in the previous comment was that, while the risk may be less with a lower platelet count, there is still a risk of blood clots due to malformed platelets. And, as platelets rise above 1 million, there is also a risk of bleeding due to platelet malfunction. I've experienced nose bleeds and abnormal bleeding even with my platelet count being less than a million. Thankfully, I've never had a blood clot!